1) Antibiotic MA 144Al
阿克拉霉素 A
2) Aclacinomycin A
阿克拉霉素A
1.
Study on the pharmacokinetics of lyophilized injection of aclacinomycin A solid lipid nanoparticles in rabbit;
阿克拉霉素A固体脂质纳米粒冻干针剂在家兔体内药动学
2.
OBJECTIVE To investigate the quality control and its tissue distribution of the prepared liver targeted aclacinomycin A solid lipid nanoparticles(ACM-SLN).
目的为促进固体脂质纳米粒(SLN)的发展,提高阿克拉霉素A(ACM-A)的疗效,制备具有肝靶向的阿克拉霉素A固体脂质纳米粒(ACM-SLN)冻干针剂,并对其质量和体内组织分布进行研究。
3.
OBJECTIVE To prepare aclacinomycin A(ACA)long circulation microemulsions (ALM) and evaluate its acute toxicity and anticancer effect in cancer small dosage chemotherapy.
目的:制备阿克拉霉素A的长循环微乳(aclacinomycin A long circulation micoremulsions,ALM)用于肿瘤的小剂量化疗。
3) aclacinomycin
阿克拉霉素
1.
Sensitivity of survivin-positive primary acute leukemia cells to aclacinomycin and cytarabine;
阿克拉霉素联合阿糖胞苷对survivin基因表达的原代急性白血病细胞增殖的影响
2.
Purpose The objective of this study is to prepare magnetic nanoparicles for drug delivery system with polybutylcyanoacrylate(PBCA)and aclacinomycin A (ACM-A).
目的 制备纳米级磁性阿克拉霉素微粒 ,考察其理化性质和磁场响应性。
3.
To explore the correlation between the cellular inhibitors of apoptosis proteins (cIAPs) and the apoptosis of myelodysplastic syndrome (MDS ) cell line (RAEB type) cells induced by aclacinomycin (ACM), the apoptosis of MDS cell line MUTZ-1 cells induced by ACM was analyzed with terminal de oxyribonucleotidy transferase mediated dUTP-biotin nick end labeling (TUNEL) te c hnique.
为了探讨阿克拉霉素 (aclacinomycin ,ACM)诱导骨髓增生异常综合征 (MDS)细胞凋亡与凋亡蛋白抑制因子 (IAP)的关系 ,以DNA片段原位末端 (TUNEL)标记方法检测MDS细胞株MUTZ 1细胞 (RAEB型 )经ACM作用后的TUNEL阳性细胞 ,并用RT PCR技术检测cIAP1及cIAP2mRNA表达水平的变化。
4) Aclarubicin
阿克拉霉素
1.
Effects of Hydroxylcamptothecinum. Aclarubicin. Triptolide on the Cell Cycle of Cultured Vascular Smooth Muscle Cells;
羟基喜树碱、雷公藤甲素、阿克拉霉素影响兔血管平滑肌细胞周期进程的研究
2.
The Effects of Aclarubicin on Mitoxantrone Killing of Hela Cells;
阿克拉霉素对米托蒽醌杀伤Hela细胞的影响
3.
Methods Thirteen patients with AML were treated with CAG regimen consisting of low-dose arabinosylcytosine(Ara-c),aclarubicin and granulocyte colony-stimulating factor(G-CSF).
方法13例初治AML患者予以含G-CSF、低剂量阿糖胞苷(Ara-C)和阿克拉霉素(ACR)的CAG方案。
5) aclacinomycin B
阿克拉霉素B
6) aclacinomycin A (ACM-A)
阿克拉希霉素A
补充资料:阿克拉霉素 A
分子式:C42H53NO15
分子量:暂无
CAS号:57576-44-0
性质:暂无
制备方法:暂无
用途:抗肿瘤抗生素,主要用于肺癌、乳腺癌、消化道癌、急性白血病等。
分子量:暂无
CAS号:57576-44-0
性质:暂无
制备方法:暂无
用途:抗肿瘤抗生素,主要用于肺癌、乳腺癌、消化道癌、急性白血病等。
说明:补充资料仅用于学习参考,请勿用于其它任何用途。
参考词条